|
|
|
|
|
|
|
SIZE:
|
|
|
|
GENERIC NAME:
|
|
|
|
MANUFACTURER:
|
|
|
|
UNIT:
|
|
|
|
ADMINISTRATION ROUTE:
|
|
|
|
FDA PREGNANCY GROUP:
|
|
C
|
|
INDICATIONS:
|
|
Arrhythmia, ventricular |
|
Fibrillation, paroxysmal atrial |
|
Flutter, paroxysmal atrial |
|
Tachycardia, paroxysmal supraventricular |
|
Tachycardia, ventricular |
| |
|
|
SIDE EFFECTS:
|
|
Arrhythmias, including new or worsened ventricular tachyarrhythmias, increased frequency of premature ventricular contractions, or new supraventricular arrhythmias |
|
chest pain |
|
congestive heart failure |
|
trembling or shaking |
|
Hepatic function impairment |
|
Blurred vision or seeing spots |
|
dizziness or lightheadedness |
|
Anxiety or mental depression |
|
constipation |
|
headache |
|
nausea or vomiting |
|
skin rash |
|
stomach pain or loss of appetite |
|
unusual tiredness or weakness |
|
|
ABSOLUTE
CONTRAINDICATIONS :
|
|
|
|
RELATIVE
CONTRAINDICATIONS : |
|
>> Cardiogenic shock |
|
Congestive heart failure |
|
>> Hepatic function impairment |
|
Hypokalemia or hyperkalemia |
|
Myocardial infarction, history of, with associated left ventricular function impairment |
|
Renal function impairment |
|
Sensitivity to flecainide |
|
>> Sick sinus syndrome |
|
|
ADULT DOSE:
|
|
Paroxysmal supraventricular tachycardias or paroxysmal atrial fibrillation/flutter-Oral, 50 mg every twelve hours, the dosage being increased in increments of 50 mg two times a day every four days as needed and tolerated.
Sustained ventricular tachycardia-Initial: Oral, 100 mg every twelve hours, the dosage being increased in increments of 50 mg two times a day every four days as needed and tolerated.
Note: In patients with severe renal function impairment (creatinine clearance of 35 mL per minute per 1.73 square meters of body surface or less), an initial dose of 100 mg once a day or 50 mg every twelve hours is recommended, and dosage should be adjusted on the basis of frequent plasma concentration determinations .
In patients with less severe renal function impairment, an initial dose of 100 mg every twelve hours may be used; plasma concentration determinations may be useful in dosage adjustment .
Maintenance: Oral, up to 150 mg every twelve hours. |
|
MAXIMUM ADULT DOSE:
|
|
Paroxysmal supraventricular arrhythmias-Up to 300 mg per day.
Sustained ventricular tachycardia-Up to 400 mg per day. |
|
PEDIATRIC DOSE:
|
|
Safety and efficacy have not been established .
|
|
MAXIMUM PEDIATRIC
DOSE:
|
|
|
|
ELDERLY DOSE:
|
|
|
|
|
|
|
|